This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (886)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Oncology  • Lung Cancer  • Pulmonary Diseases, Other  • Randomized Controlled Trial  • Alert me on articles by topic

A Randomized Trial

Mark G. Kris, MD; Ronald B. Natale, MD; Roy S. Herbst, MD; Thomas J. Lynch, Jr, MD; Diane Prager, MD; Chandra P. Belani, MD; Joan H. Schiller, MD; Karen Kelly, MD; Harris Spiridonidis, MD; Alan Sandler, MD; Kathy S. Albain, MD; David Cella, PhD; Michael K. Wolf, PhD; Steven D. Averbuch, MD; Judith J. Ochs, MD; Andrea C. Kay, MD

JAMA. 2003;290:2149-2158.

Context  More persons in the United States die from non–small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined. In preclinical testing, oral gefitinib inhibited the growth of NSCLC tumors that express the epidermal growth factor receptor (EGFR), a mediator of cell signaling, and phase 1 trials have demonstrated that a fraction of patients with NSCLC progressing after chemotherapy experience both a decrease in lung cancer symptoms and radiographic tumor shrinkages with gefitinib.

Objective  To assess differences in symptomatic and radiographic response among patients with NSCLC receiving 250-mg and 500-mg daily doses of gefitinib.

Design, Setting, and Patients  Double-blind, randomized phase 2 trial conducted from November 2000 to April 2001 in 30 US academic and community oncology centers. Patients (N = 221) had either stage IIIB or IV NSCLC for which they had received at least 2 chemotherapy regimens.

Intervention  Daily oral gefitinib, either 500 mg (administered as two 250-mg gefitinib tablets) or 250 mg (administered as one 250-mg gefitinib tablet and 1 matching placebo).

Main Outcome Measures  Improvement of NSCLC symptoms (2-point or greater increase in score on the summed lung cancer subscale of the Functional Assessment of Cancer Therapy-Lung [FACT-L] instrument) and tumor regression (>50% decrease in lesion size on imaging studies).

Results  Of 221 patients enrolled, 216 received gefitinib as randomized. Symptoms of NSCLC improved in 43% (95% confidence interval [CI], 33%-53%) of patients receiving 250 mg of gefitinib and in 35% (95% CI, 26%-45%) of patients receiving 500 mg. These benefits were observed within 3 weeks in 75% of patients. Partial radiographic responses occurred in 12% (95% CI, 6%-20%) of individuals receiving 250 mg of gefitinib and in 9% (95% CI, 4%-16%) of those receiving 500 mg. Symptoms improved in 96% of patients with partial radiographic responses. The overall survival at 1 year was 25%. There were no significant differences between the 250-mg and 500-mg doses in rates of symptom improvement (P = .26), radiographic tumor regression (P = .51), and projected 1-year survival (P = .54). The 500-mg dose was associated more frequently with transient acne-like rash (P = .04) and diarrhea (P = .006).

Conclusions  Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.

Author Affiliations: Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weill Medical College of Cornell University, New York, NY (Dr Kris); Cedars-Sinai Comprehensive Cancer Center, Los Angeles, Calif (Dr Natale); University of Texas M. D. Anderson Cancer Center, Houston (Dr Herbst); Massachusetts General Hospital Cancer Center, Boston (Dr Lynch); UCLA Medical Center, Los Angeles, Calif (Dr Prager); University of Pittsburgh Cancer Institute, Pittsburgh, Pa (Dr Belani); University of Wisconsin Hospital, Madison (Dr Schiller); University of Colorado Health Sciences Center, Denver (Dr Kelly); Hematology Oncology Consultants Inc, Columbus, Ohio (Dr Spiridonidis); Vanderbilt University, Nashville, Tenn (Dr Sandler); Loyola University Medical Center, Maywood, Ill (Dr Albain); Northwestern University, Evanston, Ill (Dr Cella); AstraZeneca Pharmaceuticals, Wilmington, Del (Drs Wolf, Averbuch, Ochs, and Kay).

RELATED LETTERS

Predictors of Clinical Response of Non–Small Cell Cancer to Gefitinib
Andrea Ardizzoni and Marcello Tiseo
JAMA. 2004;291(13):1563.
EXTRACT | FULL TEXT  

Predictors of Clinical Response of Non–Small Cell Cancer to Gefitinib—Reply
Mark G. Kris, Andrea C. Kay, Judith J. Ochs, and Michael K. Wolf
JAMA. 2004;291(13):1563-1564.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

First- or Second-line Therapy with Gefitinib Produces Equal Survival in Non-Small Cell Lung Cancer
Wu et al.
Am. J. Respir. Crit. Care Med. 2008;178:847-853.
ABSTRACT | FULL TEXT  

Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer
Pantaleo et al.
Ann Oncol 2008;0:mdn625v1-mdn625.
ABSTRACT | FULL TEXT  

Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma
Wu et al.
Eur Respir J 2008;32:924-930.
ABSTRACT | FULL TEXT  

A Pilot Surrogate Endpoint Biomarker Study of Celecoxib in Oral Premalignant Lesions
Wirth et al.
Cancer Prevention Research 2008;1:339-348.
ABSTRACT | FULL TEXT  

A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
Arteaga et al.
Clin. Cancer Res. 2008;14:6277-6283.
ABSTRACT | FULL TEXT  

Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer
Hirsch et al.
Clin. Cancer Res. 2008;14:6317-6323.
ABSTRACT | FULL TEXT  

Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non-Small-Cell Lung Cancer
Barve et al.
JCO 2008;26:4418-4425.
ABSTRACT | FULL TEXT  

The Translational Research Working Group Developmental Pathway for Anticancer Agents (Drugs or Biologics)
Schilsky et al.
Clin. Cancer Res. 2008;14:5685-5691.
ABSTRACT | FULL TEXT  

Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non-Small-Cell Lung Cancer
Maruyama et al.
JCO 2008;26:4244-4252.
ABSTRACT | FULL TEXT  

Gefitinib Versus Vinorelbine in Chemotherapy-Naive Elderly Patients With Advanced Non-Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study
Crino et al.
JCO 2008;26:4253-4260.
ABSTRACT | FULL TEXT  

Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
Zhu et al.
JCO 2008;26:4268-4275.
ABSTRACT | FULL TEXT  

Speeding up the Evaluation of New Agents in Cancer
Parmar et al.
JNCI J Natl Cancer Inst 2008;100:1204-1214.
ABSTRACT | FULL TEXT  

Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?
Stinchcombe and Socinski
The Oncologist 2008;13:933-944.
ABSTRACT | FULL TEXT  

Case 23-2008 -- A 26-Year-Old Man with Back Pain and a Mass in the Lung
Sequist et al.
NEJM 2008;359:405-414.
FULL TEXT  

Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells
Ko et al.
Carcinogenesis 2008;29:1448-1458.
ABSTRACT | FULL TEXT  

From Nihilism to Individualism: The Evolution of Lung Cancer Therapy
Khuri and Roman
Am. J. Respir. Crit. Care Med. 2008;177:1299-1300.
FULL TEXT  

Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non-Small-Cell Lung Cancer: SWOG S0023
Kelly et al.
JCO 2008;26:2450-2456.
ABSTRACT | FULL TEXT  

First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
Sequist et al.
JCO 2008;26:2442-2449.
ABSTRACT | FULL TEXT  

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Engelman and Janne
Clin. Cancer Res. 2008;14:2895-2899.
ABSTRACT | FULL TEXT  

Targeting Growth Factors in Lung Cancer
Hodkinson et al.
Chest 2008;133:1209-1216.
ABSTRACT | FULL TEXT  

Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03
D'Addario et al.
Ann Oncol 2008;19:739-745.
ABSTRACT | FULL TEXT  

18F-Fluoro-2-Deoxy-Glucose Uptake Predicts Clinical Outcome in Patients with Gefitinib-Treated Non-Small Cell Lung Cancer
Na et al.
Clin. Cancer Res. 2008;14:2036-2041.
ABSTRACT | FULL TEXT  

The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non-Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib
Fidler et al.
Clin. Cancer Res. 2008;14:2088-2094.
ABSTRACT | FULL TEXT  

Carcinoma of the bronchus 60 years later
Silvestri and Spiro
Postgrad. Med. J. 2008;84:182-187.
FULL TEXT  

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib
Miller et al.
JCO 2008;26:1472-1478.
ABSTRACT | FULL TEXT  

EGFR Antagonists in Cancer Treatment
Ciardiello and Tortora
NEJM 2008;358:1160-1174.
FULL TEXT  

Is Response Rate Relevant to the Phase II Trial Design of Targeted Agents?
Dowlati and Fu
JCO 2008;26:1204-1205.
FULL TEXT  

Enzastaurin, an Oral Serine/Threonine Kinase Inhibitor, As Second- or Third-Line Therapy of Non-Small-Cell Lung Cancer
Oh et al.
JCO 2008;26:1135-1141.
ABSTRACT | FULL TEXT  

Epidermal Growth Factor Receptor (EGFR) High Gene Copy Number and Activating Mutations in Lung Adenocarcinomas Are Not Consistently Accompanied by Positivity for EGFR Protein by Standard Immunohistochemistry
Pinter et al.
J. Mol. Diagn. 2008;10:160-168.
ABSTRACT | FULL TEXT  

Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments
Brandes et al.
Clin. Cancer Res. 2008;14:957-960.
ABSTRACT | FULL TEXT  

Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models
Wang et al.
Molecular Cancer Therapeutics 2008;7:407-417.
ABSTRACT | FULL TEXT  

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
Rosell et al.
Ann Oncol 2008;19:362-369.
ABSTRACT | FULL TEXT  

Revoking the Privilege: Targeting HER2 in the Central Nervous System
Contessa and Hamstra
Mol. Pharmacol. 2008;73:271-273.
ABSTRACT | FULL TEXT  

Epidermal Growth Factor Receptor Signaling in Adenocarcinomas With Bronchioloalveolar Components
Sarkaria et al.
Ann. Thorac. Surg. 2008;85:216-223.
ABSTRACT | FULL TEXT  

Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment
Tan et al.
Ann Oncol 2008;19:185-190.
ABSTRACT | FULL TEXT  

Novel and Targeted Agents for Small Cell Lung Cancer
Johnson et al.
Am Soc Clin Oncol Ed Book 2008;2008:363-367.
ABSTRACT | FULL TEXT  

Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer
de Marinis and Grossi
The Oncologist 2008;13:14-20.
ABSTRACT | FULL TEXT  

Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer
Stinchcombe and Socinski
The Oncologist 2008;13:28-36.
ABSTRACT | FULL TEXT  

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
Engelman et al.
Cancer Res. 2007;67:11924-11932.
ABSTRACT | FULL TEXT  

Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma
Thomas et al.
Clin. Cancer Res. 2007;13:7086-7092.
ABSTRACT | FULL TEXT  

Buccal Mucosa Cells as In vivo Model to Evaluate Gefitinib Activity in Patients with Advanced Non Small Cell Lung Cancer
Loprevite et al.
Clin. Cancer Res. 2007;13:6518-6526.
ABSTRACT | FULL TEXT  

A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response
Ferry et al.
Clin. Cancer Res. 2007;13:5869-5875.
ABSTRACT | FULL TEXT  

Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers
Doody et al.
Molecular Cancer Therapeutics 2007;6:2642-2651.
ABSTRACT | FULL TEXT  

Expression of epidermal growth factor (EGF)/transforming growth factor-{alpha} by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice
Wu et al.
Molecular Cancer Therapeutics 2007;6:2652-2663.
ABSTRACT | FULL TEXT  

Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non Small-Cell Lung Cancer
Heymach et al.
JCO 2007;25:4270-4277.
ABSTRACT | FULL TEXT  

Epidermal Growth Factor Receptor Mutation Detection Using High-Resolution Melting Analysis Predicts Outcomes in Patients with Advanced Non Small Cell Lung Cancer Treated with Gefitinib
Takano et al.
Clin. Cancer Res. 2007;13:5385-5390.
ABSTRACT | FULL TEXT  

Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non Small-Cell Lung Cancer
Janne et al.
JCO 2007;25:3936-3944.
ABSTRACT | FULL TEXT  

Diagnostic Surgical Pathology in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Schwartz and Henson
Chest 2007;132:78S-93S.
ABSTRACT | FULL TEXT  

Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus
Riely et al.
Clin. Cancer Res. 2007;13:5150-5155.
ABSTRACT | FULL TEXT  

Bronchioloalveolar Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Arenberg
Chest 2007;132:306S-313S.
ABSTRACT | FULL TEXT  

Epidermal Growth Factor Receptors with Tyrosine Kinase Domain Mutations Exhibit Reduced Cbl Association, Poor Ubiquitylation, and Down-regulation but Are Efficiently Internalized
Padron et al.
Cancer Res. 2007;67:7695-7702.
ABSTRACT | FULL TEXT  

Combination Therapy With Gefitinib and Rofecoxib in Patients With Platinum-Pretreated Relapsed Non Small-Cell Lung Cancer
O'Byrne et al.
JCO 2007;25:3266-3273.
ABSTRACT | FULL TEXT  

Epidermal growth factor receptor status in anaplastic thyroid carcinoma
Lee et al.
J. Clin. Pathol. 2007;60:881-884.
ABSTRACT | FULL TEXT  

HKI-272 in Non Small Cell Lung Cancer
Wong
Clin. Cancer Res. 2007;13:4593s-4596s.
ABSTRACT | FULL TEXT  

Antibodies to the Epidermal Growth Factor Receptor in Non Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab
Socinski
Clin. Cancer Res. 2007;13:4597s-4601s.
ABSTRACT | FULL TEXT  

Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors
Bonomi et al.
Clin. Cancer Res. 2007;13:4606s-4612s.
ABSTRACT | FULL TEXT  

Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
Karamouzis et al.
JAMA 2007;298:70-82.
ABSTRACT | FULL TEXT  

Lapatinib-Associated Toxicity and Practical Management Recommendations
Moy and Goss
The Oncologist 2007;12:756-765.
ABSTRACT | FULL TEXT  

Can Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Be Overcome by Different Small-Molecule Tyrosine Kinase Inhibitors?
Bunn
JCO 2007;25:2504-2505.
FULL TEXT  

Phase II Study of Erlotinib in Advanced Non-Small-Cell Lung Cancer After Failure of Gefitinib
Cho et al.
JCO 2007;25:2528-2533.
ABSTRACT | FULL TEXT  

Phase II Study: Integrated Palliative Care in Newly Diagnosed Advanced Non-Small-Cell Lung Cancer Patients
Temel et al.
JCO 2007;25:2377-2382.
ABSTRACT | FULL TEXT  

Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization-Positive/Phospho-Akt-Positive or Never Smoker Patients With Advanced Non-Small-Cell Lung Cancer: The ONCOBELL Trial
Cappuzzo et al.
JCO 2007;25:2248-2255.
ABSTRACT | FULL TEXT  

Pharmacogenomics of Anticancer Agents: Implications for Clinical Pharmacy Practice
Grabinski
Journal of Pharmacy Practice 2007;20:246-251.
ABSTRACT  

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma
Frederick et al.
Molecular Cancer Therapeutics 2007;6:1683-1691.
ABSTRACT | FULL TEXT  

KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
Massarelli et al.
Clin. Cancer Res. 2007;13:2890-2896.
ABSTRACT | FULL TEXT  

Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non small Cell Lung Cancer Cells to Treatment with Gefitinib
Morgillo et al.
Clin. Cancer Res. 2007;13:2795-2803.
ABSTRACT | FULL TEXT  

Epidermal Growth Factor Receptor Inhibitor-Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management
Lynch et al.
The Oncologist 2007;12:610-621.
ABSTRACT | FULL TEXT  

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
Hirsch et al.
Ann Oncol 2007;18:752-760.
ABSTRACT | FULL TEXT  

Uncommon tumors and exceptional therapies: paradox or paradigm?
Braiteh and Kurzrock
Molecular Cancer Therapeutics 2007;6:1175-1179.
ABSTRACT | FULL TEXT  

clairvoyance or reliable prediction of the future?
van Zandwijk and van de Vijver
Ann Oncol 2007;18:407-408.
FULL TEXT  

Phase II Clinical Trial of Chemotherapy-Naive Patients >= 70 Years of Age Treated With Erlotinib for Advanced Non-Small-Cell Lung Cancer
Jackman et al.
JCO 2007;25:760-766.
ABSTRACT | FULL TEXT  

The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents
Tabernero
Mol Cancer Res 2007;5:203-220.
ABSTRACT | FULL TEXT  

Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer
Jimeno et al.
Molecular Cancer Therapeutics 2007;6:1079-1088.
ABSTRACT | FULL TEXT  

Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer
Zhang and Chang
J. Med. Genet. 2007;44:166-172.
ABSTRACT | FULL TEXT  

Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Sequist
The Oncologist 2007;12:325-330.
ABSTRACT | FULL TEXT  

Gefitinib Reverses TRAIL Resistance in Human Bladder Cancer Cell Lines via Inhibition of AKT-Mediated X-Linked Inhibitor of Apoptosis Protein Expression
Shrader et al.
Cancer Res. 2007;67:1430-1435.
ABSTRACT | FULL TEXT  

Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non-Small-Cell Lung Cancer
Sequist et al.
JCO 2007;25:587-595.
ABSTRACT | FULL TEXT  

Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments
Steeghs et al.
Ann. Surg. Oncol. 2007;14:942-953.
ABSTRACT | FULL TEXT  

p53 Enhances Gefitinib-Induced Growth Inhibition and Apoptosis by Regulation of Fas in Non-Small Cell Lung Cancer
Rho et al.
Cancer Res. 2007;67:1163-1169.
ABSTRACT | FULL TEXT  

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
Ohe et al.
Ann Oncol 2007;18:317-323.
ABSTRACT | FULL TEXT  

Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Okano et al.
Clin. Cancer Res. 2007;13:799-805.
ABSTRACT | FULL TEXT  

Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Toschi and Cappuzzo
The Oncologist 2007;12:211-220.
ABSTRACT | FULL TEXT  

Targeting HER2 in Prostate Cancer: Where to Next?
Solit and Rosen
JCO 2007;25:241-243.
FULL TEXT  

PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors
Mellinghoff et al.
Clin. Cancer Res. 2007;13:378-381.
ABSTRACT | FULL TEXT  

Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study
van Puijenbroek et al.
Eur Respir J 2007;29:128-133.
ABSTRACT | FULL TEXT  

Molecular correlates of gefitinib responsiveness in human bladder cancer cells
Shrader et al.
Molecular Cancer Therapeutics 2007;6:277-285.
ABSTRACT | FULL TEXT  

Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway
Rosell et al.
Clin. Cancer Res. 2006;12:7222-7231.
ABSTRACT | FULL TEXT  

Update on Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
Riely et al.
Clin. Cancer Res. 2006;12:7232-7241.
ABSTRACT | FULL TEXT  

CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors
Li et al.
JNCI J Natl Cancer Inst 2006;98:1714-1723.
ABSTRACT | FULL TEXT  

Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib
Cusatis et al.
JNCI J Natl Cancer Inst 2006;98:1739-1742.
ABSTRACT | FULL TEXT  

Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling
Kobayashi et al.
Cancer Res. 2006;66:11389-11398.
ABSTRACT | FULL TEXT  

Effect of an Epidermal Growth Factor Receptor Inhibitor in Mouse Models of Lung Cancer
Yan et al.
Mol Cancer Res 2006;4:971-981.
ABSTRACT | FULL TEXT  

Carcinoma of the bronchus 60 years later.
Silvestri and Spiro
Thorax 2006;61:1023-1028.
FULL TEXT